ALKSAlkermes plc
Price
+46%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Ireland, we also have a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Alkermes plc (ALKS) reported revenue of $496M in Q2 2026 (quarter ended Jun 30, 2026), up 27% from the same quarter a year earlier. That came with a gross margin of 80% and net income of $501K (0.1% of revenue). For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in Q2 2026 was Vivitrol at $124M, 23% of the disclosed total, just ahead of Aristada And Aristada Initio at 18%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026On September 21, 2026, the Company announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the Company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD).Regulation FD disclosure · Form 8-K
- Sep 16, 2026On September 14, 2026, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of …Director or officer change · Form 8-K
- Aug 12, 2026Term Loan Credit Facilities On August 12, 2026, Alkermes plc (the “Company”) entered into Amendment No. 1 to Credit Agreement (the “Amendment”), which amends the Credit Agreement, dated as of February 12, 2026 (the “Credit Agreement”), among the Company, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $544.4MThe company’s own SEC segment disclosure.
- Vivitrol$124.5M23%
- Aristada And Aristada Initio$96.7M18%
- LUMRYZ$96.6M18%
- LYBALVI$94.0M17%
- Manufactured Product And Royalty$84.3M15%
- Royalty$27.5M5%
- Other (1)$20.9M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 41 by RyuScore